Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 19/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 18/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 8/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 8/20 | 1.00 |
| ▸ | RICTOR | Q6R327 | 7/20 | 1.00 |
| ▸ | MAPKAP1 | Q9BPZ7 | 7/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.59 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.59 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17748623 | 1.00 | MTOR (1.00) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL24055185 | 0.93 | MTOR (0.98) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL17748735 | 0.88 | MTOR (1.00) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL17748702 | 0.88 | MTOR (0.78) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL17748707 | 0.88 | MTOR (0.78) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL29880214 | 0.88 | MTOR (0.78) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL29592956 | 0.84 | PIK3CA (0.83) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL22838416 | 0.84 | MTOR (0.75) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL17748693 | 0.83 | MTOR (0.71) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL29880060 | 0.83 | MTOR (0.71) | MTORPIK3CARPTORMLST8RICTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109414415-B | Treatment of skin lesions | 拓客股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-20260062419-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-12497407-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2025-12-16 | — | — | US | disclosed |
| CN-109414415-B | Treatment of skin lesions | 拓客股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-109475560-B | Treatment of neurological disorders | 巴塞尔大学 | 2023-05-02 | — | — | CN | disclosed |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2023-01-19 | — | — | US | disclosed |
| US-11414426-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2022-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062419-A1 | TREATMENT OF SKIN DISORDERS | POLR1C, CCR1, COL1A1 | MTOR 3397/4885PIK3CA 3453/4885RPTOR 2446/4885 |
| US-12497407-B2 | Treatment of skin disorders | RXFP3, CCR3, CBR3 | MTOR 3212/4885PIK3CA 4158/4885RPTOR 1660/4885 |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | RXFP3, CCR3, CBR3 | MTOR 3212/4885PIK3CA 4158/4885RPTOR 1660/4885 |
| US-11414426-B2 | Treatment of skin disorders | RXFP3, CBR3, CXCR3 | MTOR 2897/4885PIK3CA 3974/4885RPTOR 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.